{
  "id": "602752681cb411341a0000e7",
  "type": "list",
  "question": "Which drugs are included in the VIFUP regimen for breast cancer?",
  "ideal_answer": "ViFuP includes vinorelbine, cisplatin and continuous infusion of 5-fluorouracil.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/18595702",
    "http://www.ncbi.nlm.nih.gov/pubmed/12239445",
    "http://www.ncbi.nlm.nih.gov/pubmed/11911307",
    "http://www.ncbi.nlm.nih.gov/pubmed/11249057",
    "http://www.ncbi.nlm.nih.gov/pubmed/14504046"
  ],
  "snippets": [
    {
      "text": "PATIENTS AND METHODS: Breast cancer patients, clinical stages T2-T3, N0-N2, M0, and Ki-67 labelling index >/= 20%, were treated every 3 weeks with a maximum of six courses of vinorelbine 20 mg total dose intravenously (i.v.) on days 1 and 3, cisplatin 60 mg/ m(2) i.v. on day 1 and 5-FU 200 mg/m(2)/day as a continuous infusion (ViFuP regimen). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14504046",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "METHODS: 25 patients with locally advanced head and neck cancer were treated with 4 cycles of vinorelbine (20 mg i.v. day 1, 3), cisplatin (60 mg/m(2) i.v. day 1) and 5-fluorouracil (200 mg/m(2) continuous i.v. infusion day 1-21) (ViFuP regimen) followed by bifractionated radiotherapy (bidRT) up to 74.4 Gy in 62 fractions of 1.2 Gy twice daily.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12239445",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11249057",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We assessed efficacy in terms of response rate and time to progression of a combination with continuous infusion 5-fluorouracil (5-FU), vinorelbine and cisplatin (ViFuP regimen), as a first or subsequent line treatment for metastatic breast cancer patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11249057",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The feasibility and efficacy of a regimen containing vinorelbine (V), cisplatin (P) and 5-fluorouracil (5-Fu) as continuous infusion (ViFuP regimen) for patients with locally advanced breast cancer were evaluated. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11911307",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Patients with large operable (cT2-T3, N0-2, M0), ER > or =10% breast cancer were treated in two consecutive studies with preoperative chemotherapy (Study I: six courses of either fluorouracil, leucovorin, vinorelbine (FLN), or vinorelbine, cisplatin, and continuous infusion of fluorouracil (ViFuP), at the discretion of the treating physician; Study II: capecitabine and oral vinorelbine (CAVINO)). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18595702",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The feasibility and efficacy of a regimen containing vinorelbine (V), cisplatin (P) and 5-fluorouracil (5-Fu) as continuous infusion (ViFuP regimen) for patients with locally advanced breast cancer were evaluated.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11911307",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Patients with large operable (cT2-T3, N0-2, M0), ER > or =10% breast cancer were treated in two consecutive studies with preoperative chemotherapy (Study I: six courses of either fluorouracil, leucovorin, vinorelbine (FLN), or vinorelbine, cisplatin, and continuous infusion of fluorouracil (ViFuP), at the discretion of the treating physician; Study II: capecitabine and oral vinorelbine (CAVINO)).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18595702",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "e feasibility and efficacy of a regimen containing vinorelbine (V), cisplatin (P) and 5-fluorouracil (5-Fu) as continuous infusion (ViFuP regimen) for patients with locally advanced breast cancer were evaluated. Twenty-s",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11911307",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We assessed efficacy in terms of response rate and time to progression of a combination with continuous infusion 5-fluorouracil (5-FU), vinorelbine and cisplatin (ViFuP regimen), as a first or subsequent line treatment for metastatic breast cancer patients.P",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11249057",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "uitable. We assessed efficacy in terms of response rate and time to progression of a combination with continuous infusion 5-fluorouracil (5-FU), vinorelbine and cisplatin (ViFuP regimen), as a first or subsequent line treatment for metastatic breast cancer patients.PATIENTS AND METHODS: One hundred consecutive patients with advanced breast cancer were treated with 5-FU 200 mg/m2 administered continuously through a permanent central venous line; vinorelbine was given on days 1 and 3 at a dose of 20 mg and cisplatin was admin",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11249057",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "vinorelbine, cisplatin, 5-fluorouracil"
}